CONBA(SH:600572) Xin Lang Cai Jing·2025-07-31 08:25Core Viewpoint - 康恩贝's subsidiary, Hangzhou Kang En Bei, has received approval from the National Medical Products Administration for the drug Aminocaproic Acid Tablets, which is expected to positively impact the company's performance [1] Group 1: Drug Approval Details - The approved drug is specified as 0.25g Aminocaproic Acid Tablets, primarily used for various bleeding conditions caused by primary fibrinolysis and secondary hyperfibrinolysis due to disseminated intravascular coagulation [1] - The registration application was submitted in April 2024 and has now been approved, indicating a successful regulatory process [1] Group 2: Financial Implications - Hangzhou Kang En Bei has invested approximately 6.27 million yuan in research and development for this drug [1] - The drug is considered to have passed the consistency evaluation for generic drugs according to national policies, which is expected to have a positive impact on the company's financial performance [1]